Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Leuprorelin, also known as Leuprolide acetate, is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH). Its molecular formula is C59H82N16O14, and it carries the CAS Registry Number 53714-56-0. This pharmaceutical agent acts as a potent GnRH agonist, initially stimulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. However, with continuous administration, it causes downregulation and desensitization of GnRH receptors, leading to a profound suppression of sex steroid production in both males and females.
The primary clinical application of Leuprorelin involves the management of hormone-dependent conditions. In men, it is extensively used for the treatment of advanced prostate cancer. By suppressing testosterone levels to castrate ranges, it inhibits tumor growth and slows disease progression. In women, it serves as a critical therapy for endometriosis, uterine fibroids (leiomyomas), and central precocious puberty. For endometriosis and fibroids, the drug induces a hypoestrogenic state that shrinks ectopic tissue and reduces fibroid size, often alleviating pain and abnormal bleeding. In cases of central precocious puberty, it delays premature sexual development by halting the early activation of the hypothalamic-pituitary-gonadal axis.
Leuprorelin is typically administered via intramuscular or subcutaneous injection in sustained-release formulations, available as monthly, three-monthly, or six-monthly depot preparations. While generally well-tolerated, common side effects are related to its hormonal suppression mechanism. Men may experience hot flashes, decreased libido, and erectile dysfunction, while women often report similar vasomotor symptoms, vaginal dryness, and mood changes. Long-term use requires monitoring for bone mineral density loss due to estrogen or testosterone deprivation. Despite these potential adverse effects, Leuprorelin remains a cornerstone in modern endocrinology and oncology, offering significant therapeutic benefits for patients suffering from complex hormonal disorders. Its efficacy in controlling disease progression and improving quality of life has established it as a standard-of-care medication globally.